Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
American physicians have commonly practiced thrombolytic therapy for acute myocardial infarction with the recombinant form of tissue plasminogen activator (rt-PA), although its cost is much higher than that of streptokinase. The greater popularity of rt-PA is based on the belief that it is a more effective and a safer drug for achieving myocardial salvage and mortality reduction. However, a series of studies testing this assumption have not substantiated its greater efficacy or safety with respect to not only streptokinase but also urokinase and anisoylated plasminogen-streptokinase activator complex (APSAC). This editorial reviews the sequence of events that led to the creation of the rt-PA image, the mistaken premises on which it was based and the questions that need to be addressed if we are to strengthen the scientific method for evaluating similar types of drugs and its influence on practice habits including the costs to the health system.
S
S
Sherry
V J
VJ
Marder
D016255:Anistreplase / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010818:Practice Patterns, Physicians'; D011994:Recombinant Proteins / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D011994:Recombinant Proteins; D016255:Anistreplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator